{"id":"W2336769999","doi":"10.1200/jco.2006.24.18_suppl.17078","title":"Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Achieve Life Sciences (Canada)","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; Clusterin; Cancer research; Stage (stratigraphy); Oncology; Deoxycytidine; Oligonucleotide; Internal medicine; Chemotherapy; Molecular biology; Apoptosis; Biology; DNA; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008521346,0.001617028,0.001621832,0.0005582221,0.0004331809,0.0008205398,0.0009459776,0.001266891,0.002191195],"category_scores_gemma":[0.0005355538,0.0007265412,0.0007799445,0.0003764745,0.000928871,0.0007826698,0.0003640453,0.002347981,0.0005663756],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162695,"about_ca_system_score_gemma":0.00193069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00116527,"about_ca_topic_score_gemma":0.003377627,"domain_scores_codex":[0.999703,0.0001222429,0.00001643258,0.00006484434,0.00002985892,0.00006348095],"domain_scores_gemma":[0.9995696,0.0000484452,0.00009500211,0.00002952305,0.0000298657,0.0002275585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5401438,0.1650824,0.0102821,0.001142736,0.001183529,0.0004963153,0.000629711,0.004777858,0.1802933,0.0004555331,0.00474444,0.09076819],"study_design_scores_gemma":[0.2616833,0.7140484,0.009740046,0.00002818765,0.00038616,0.000325392,0.0000750199,0.001159773,0.01001366,0.00009265214,0.002420678,0.00002668947],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945491,0.0007999439,0.0003428925,0.0002369749,0.00008009897,0.002544267,0.0004819947,0.00006453785,0.0009001266],"genre_scores_gemma":[0.9892347,0.001171148,0.00170503,0.0004661768,0.0001378469,0.003215289,0.001740246,0.00002933616,0.002300128],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002191195,"threshold_uncertainty_score":0.008435965,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05611860557962895,"score_gpt":0.4137367067407564,"score_spread":0.3576181011611275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}